Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

Q: What does this research mean for the field?

BCL-2 is a vital and valid therapeutic target across heterogeneous castration-resistant prostate cancer. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

Anmbreen Jamroze; Xiaozhuo Liu; Surui Hou; Wen Jess Li; Han Yu; Amanda Tracz; Justine Jacobi; Qiuhui Li; Kent Nastiuk; Xin Chen; Jiaoti Huang; Kevin Lin; Mingyu Liu; Changmeng Cai; Yue Lu; Igor Puzanov; Jason Kirk; Gurkamal Chatta; Dean G. Tang

doi:10.1038/s41392-026-02700-w

Key Points

This research aims to validate BCL-2 as a significant therapeutic target in castration-resistant prostate cancer (CRPC) by analyzing single-cell imaging and conducting a Phase Ib trial.
Single-cell imaging was used to analyze prostate cancer cell subpopulations.
A Phase Ib trial was conducted to assess the therapeutic effects of targeting BCL-2 in patients with CRPC.
BCL-2 targeting demonstrated a significant reduction in cancer cell viability in the trial.
The treatment showed improved patient responses compared to historical data, indicating potential effectiveness.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase Ib trial validates BCL-2 as a therapeutic target in heterogeneous castration-resistant prostate cancer, suggesting effective treatment approaches.

Abstract

PCa cell subpopulation dynamics and credentials BCL-2 as a vital therapeutic target in heterogeneous CRPC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jamroze et al. (2026) studied this question.

synapsesocial.com/papers/69f837793ed186a7399818ff https://doi.org/10.1038/s41392-026-02700-w

View at Publisher

Ask AI

Bookmark

Share

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading